Loading
Life sciences · Journal article
Kosin Medical Journal · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The histologic benefits demonstrated in the phase 3 ESSENCE (Effect of Semaglutide in Subjects with Noncirrhotic Nonalcoholic Steatohepatitis) trial have established semaglutide, a glucagon-like peptide-1 receptor agonist, as a leading pharmacologic option for metabolic dysfunction-associated steatohepatitis. However, the evidence comes predominantly from Western cohorts with high body mass index, raising questions about its generalizability to Asian populations, in whom metabolic dysfunction-associated steatotic liver disease (MASLD) frequently occurs at normal or near-normal body weight (“lean” MASLD). Lean MASLD is a distinct clinical phenotype characterized by visceral adiposity, sarcopenia, and genetic susceptibility rather than generalized obesity; it accounts for a substantial proportion of MASLD in Asia, with a prognosis comparable to or worse than that of non-lean disease. This review synthesizes current evidence for semaglutide in Asian and lean populations with MASLD, examines whether its hepatic benefits depend on weight loss or involve weight-independent mechanisms, and assesses safety considerations specific to lean patients. It identifies the absence of randomized semaglutide trials specifically enrolling Asian patients with biopsy-proven lean MASLD as a central evidence gap and outlines practical approaches to address it, including cohorts assessed with noninvasive endpoints and target trial emulation using national claims data.